[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 17 of about 17
1. Brennan B: Nasopharyngeal carcinoma. Orphanet J Rare Dis; 2006;1:23
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nasopharyngeal carcinoma (NPC) is a tumor arising from the epithelial cells that cover the surface and line the nasopharynx.
  • The tumor can extend within or out of the nasopharynx to the other lateral wall and/or posterosuperiorly to the base of the skull or the palate, nasal cavity or oropharynx.
  • Cervical lymphadenopathy is the initial presentation in many patients, and the diagnosis of NPC is often made by lymph node biopsy.
  • Symptoms related to the primary tumor include trismus, pain, otitis media, nasal regurgitation due to paresis of the soft palate, hearing loss and cranial nerve palsies.
  • The recommended treatment schedule consists of three courses of neoadjuvant chemotherapy, irradiation, and adjuvant interferon (IFN)-beta therapy.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / therapy. Nasopharyngeal Neoplasms / diagnosis. Nasopharyngeal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / diagnosis. Child. Child, Preschool. Global Health. Humans. Incidence. Infant. Infant, Newborn. Neoplasm Staging / methods. Prognosis. Radiotherapy / methods. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1978 Mar;41(3):1128-33 [638955.001]
  • [Cites] IARC Sci Publ. 1978;(20):115-29 [730188.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1980 Apr;6(4):487-91 [7390929.001]
  • [Cites] Cancer. 1981 Jan 15;47(2):360-6 [7459824.001]
  • [Cites] Cancer. 1982 Jan 1;49(1):163-9 [7053813.001]
  • [Cites] Med Pediatr Oncol. 1982;10(3):243-50 [7087893.001]
  • [Cites] Int J Cancer. 1983 Aug 15;32(2):171-6 [6874140.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1984 Sep-Oct;93(5 Pt 1):477-82 [6093669.001]
  • [Cites] Cancer Res. 1986 Feb;46(2):956-61 [3940655.001]
  • [Cites] J Laryngol Otol. 1987 Dec;101(12):1248-53 [3323380.001]
  • [Cites] Int J Cancer. 1988 Aug 15;42(2):176-81 [2841245.001]
  • [Cites] Pediatr Hematol Oncol. 1986;3(2):143-52 [3153224.001]
  • [Cites] Cancer Res. 1994 Aug 1;54(15):4003-6 [8033130.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Jun;3(4):305-10 [8061578.001]
  • [Cites] Anticancer Res. 1994 May-Jun;14(3B):1357-60 [8067705.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1188-91 [10096545.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):850-7 [15641027.001]
  • [Cites] Cancer. 2005 Sep 1;104(5):1083-9 [15999363.001]
  • [Cites] Cancer Res. 1999 Nov 1;59(21):5452-5 [10554016.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2351-5 [10811107.001]
  • [Cites] J Pediatr. 1974 Jan;84(1):96-100 [12119964.001]
  • [Cites] N Engl J Med. 2004 Jun 10;350(24):2461-70 [15190138.001]
  • [Cites] Arch Surg. 1967 Feb;94(2):214-7 [6016269.001]
  • [Cites] Nature. 1970 Dec 12;228(5276):1056-8 [4320657.001]
  • [Cites] Laryngoscope. 1972 May;82(5):807-16 [4337403.001]
  • [Cites] Nat New Biol. 1973 Aug 22;244(138):245-7 [4353684.001]
  • [Cites] J Pediatr. 1975 Feb;86(2):254-8 [1111694.001]
  • [Cites] Int J Cancer. 1975 Apr 15;15(4):651-7 [1173575.001]
  • (PMID = 16800883.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 36
  • [Other-IDs] NLM/ PMC1559589
  • [General-notes] NLM/ Original DateCompleted: 20070719
  •  go-up   go-down


2. Janas A, Grzesiak-Janas G: [Non-Hodgkin extranodular lymphoma of the palate]. Pol Merkur Lekarski; 2006 Jun;20(120):705-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-Hodgkin extranodular lymphoma of the palate].
  • In most cases, the extranodular localisation of the neoplasm is alimentary tract, particularly the stomach.
  • The aim of the study is to present a patient with rarely occuring lymphoma of the soft palate.
  • The patient was qualified for chemotherapy according to CHOP scheme, in the Chair of Oncology of Medical University in Lodz.
  • The patient completed the treatment in good condition.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Palate, Soft / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Humans. Male

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17007274.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


3. Erkal HS, Serin M, Amdur RJ, Villaret DB, Stringer SP, Mendenhall WM: Squamous cell carcinomas of the soft palate treated with radiation therapy alone or followed by planned neck dissection. Int J Radiat Oncol Biol Phys; 2001 Jun 1;50(2):359-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinomas of the soft palate treated with radiation therapy alone or followed by planned neck dissection.
  • PURPOSE: The present study presents the experience at the University of Florida with treatment of unselected patients with carcinomas of the soft palate with radiation therapy (RT) alone or followed by planned neck dissection.
  • T-stage and overall treatment time significantly affected local control in multivariate analysis.
  • Overall treatment time and planned neck dissection significantly affected nodal control in multivariate analysis.
  • Overall treatment time and planned neck dissection significantly affected ultimate local-regional control in multivariate analysis.
  • Overall stage, overall treatment time, and planned neck dissection significantly affected overall survival in multivariate analysis.
  • Overall treatment time and planned neck dissection significantly affected cause-specific survival in multivariate analysis.
  • CONCLUSION: For limited carcinomas of the soft palate, RT (alone or followed by planned neck dissection) results in relatively high local-regional control and survival rates.
  • For advanced carcinomas of the soft palate, local-regional control and survival rates are relatively low and local-regional recurrence rates are substantial.
  • Advanced carcinomas of the soft palate may be better treated with RT and concomitant chemotherapy.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neck Dissection. Neoplasm Staging. Palate, Soft / pathology. Palate, Soft / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11380222.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Stambuk HE, Karimi S, Lee N, Patel SG: Oral cavity and oropharynx tumors. Radiol Clin North Am; 2007 Jan;45(1):1-20
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancers of the oral cavity and pharynx are the most common head and neck cancers in the United States, and squamous cell carcinoma is the most frequent histologic type.
  • As a general rule, surgical resection is the primary treatment for oral cavity squamous cell carcinoma, whereas oropharyngeal squamous cell carcinomas are treated with radiation with or without chemotherapy.
  • A clear understanding of the anatomy and knowledge of clinical behavior and spread patterns of oral cavity and oropharyngeal squamous cell carcinoma are essential for radiologists to make a meaningful contribution to the treatment of these patients.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Magnetic Resonance Imaging. Mouth Neoplasms / diagnosis. Oropharyngeal Neoplasms / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Follow-Up Studies. Humans. Lymphatic Metastasis. Mouth / pathology. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / radiography. Neoplasm Staging. Oropharynx / pathology. Palatal Neoplasms / diagnosis. Palatal Neoplasms / pathology. Palatal Neoplasms / radiography. Palate, Soft / pathology. Time Factors. Tonsillar Neoplasms / diagnosis. Tonsillar Neoplasms / pathology. Tonsillar Neoplasms / radiography

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17157621.001).
  • [ISSN] 0033-8389
  • [Journal-full-title] Radiologic clinics of North America
  • [ISO-abbreviation] Radiol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


5. Fritz MA, Sade B, Bauer TW, Wood BG, Lee JH: Benign fibrous histiocytoma of the pterygopalatine fossa with intracranial extension. Acta Neurochir (Wien); 2006 Jan;148(1):73-6; discussion 76

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite the histologic absence of nuclear pleomorphism, the tumor rapidly recurred after complete surgical resection.
  • The aggressive nature of our patient's tumor confirms previous observations that an aggressive radiographic appearance has prognostic value when dealing with skeletal and soft tissue tumors.
  • The benefit of multimodal therapy has not been established in these rare head and neck lesions.
  • In the subset of fibrous histiocytomas that invade bone, however adjunctive treatment with radiation and or chemotherapy may be appropriate.
  • [MeSH-major] Brain / pathology. Histiocytoma, Benign Fibrous / pathology. Neoplasm Recurrence, Local / pathology. Palate, Hard. Skull Base Neoplasms / pathology
  • [MeSH-minor] Fatal Outcome. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16200478.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


6. Laccourreye O, Hans S, Ménard M, Garcia D, Brasnu D, Holsinger FC: Transoral lateral oropharyngectomy for squamous cell carcinoma of the tonsillar region: II. An analysis of the incidence, related variables, and consequences of local recurrence. Arch Otolaryngol Head Neck Surg; 2005 Jul;131(7):592-9
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTERVENTIONS: A total of 131 (81.9%) of the 166 patients received preoperative induction chemotherapy.
  • Fifty-one patients (30.7%) underwent postoperative radiation therapy.
  • In univariate analysis, 7 variables were significantly associated with an increased risk of local failure: increasing T classification; positive margins of resection; poor clinical response to induction chemotherapy; tumor spread to the posterior pillar, posterior pharyngeal wall, and contralateral soft palate; and invasion of the junction between the tonsil and soft palate.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Neoplasm Recurrence, Local. Oropharynx / surgery. Tonsillar Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Logistic Models. Male. Middle Aged. Neoplasm Metastasis. Neoplasms, Second Primary. Otorhinolaryngologic Surgical Procedures / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16027281.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


7. Chera BS, Amdur RJ, Hinerman RW, Morris CG, Villaret DB, Werning JW, Mendenhall WM: Definitive radiation therapy for squamous cell carcinoma of the soft palate. Head Neck; 2008 Aug;30(8):1114-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Definitive radiation therapy for squamous cell carcinoma of the soft palate.
  • BACKGROUND: We report the University of Florida experience with soft-palate carcinoma treated with radiotherapy alone or combined with adjuvant chemotherapy and/or neck dissection for residual disease in the neck.
  • In multivariate analysis, overall treatment time significantly affected local and ultimate local-regional control, and nodal stage significantly affected overall survival.
  • CONCLUSIONS: The likelihood of cure after definitive radiotherapy is relatively high and is impacted by disease extent and overall treatment time.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Mouth Neoplasms / therapy. Palate, Soft / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neck Dissection. Neoplasm, Residual / surgery. Time Factors

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18615732.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. El Ghelbazouri N, Afifi Y, Benameur H, Bella A, Elhallaoui Y, Kettani F, Aït Ourhrouil M, Senouci K, Hassam B: [Oral verrucous carcinoma and human papillomavirus infection]. Ann Dermatol Venereol; 2007 Aug-Sep;134(8-9):659-62
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: A 72 year-old woman with a history of actinic cheilitis consulted for a bulky tumour of the lips and palate.
  • Clinical examination revealed a highly infiltrated labial tumour vegetating and budding, with a thick edge.
  • A bulky tumour and firm masses were seen on the hard and soft palates.
  • The immunohistochemical study showed intestinal tumour containing HPV-16 virus.
  • The central facial scan showed involvement of the nasal fossae, soft palate and lips with lysis of the upper maxilla arcade and the osseous palate.
  • The patient died a few days before the start of preoperative chemotherapy following severe deterioration of her general state.
  • Diagnosis is based on histological examination.
  • Management and treatment are not codified but surgery remains the treatment of choice and relapse is common in the case of locoregional involvement.
  • [MeSH-minor] Aged. Fatal Outcome. Female. Humans. Lip Neoplasms / pathology. Maxillary Diseases / pathology. Neoplasm Invasiveness. Nose Neoplasms / pathology. Osteolysis / pathology. Palatal Neoplasms / pathology. Palate, Hard / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17925690.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


9. Mendenhall WM, Morris CG, Amdur RJ, Hinerman RW, Mancuso AA: Parameters that predict local control after definitive radiotherapy for squamous cell carcinoma of the head and neck. Head Neck; 2003 Jul;25(7):535-42
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parameters that predict local control after definitive radiotherapy for squamous cell carcinoma of the head and neck.
  • PURPOSE: To analyze parameters that may influence the likelihood of local control after definitive radiotherapy for head and neck cancer.
  • METHODS: Between April 1980 and January 2000, 404 patients were treated with definitive RT alone (358 patients) or combined with adjuvant chemotherapy (46 patients) at our institution and were followed up for 0.25 to 20.25 years (median, 3.5 years.
  • All patients had the primary tumor volume calculated on pretreatment CT.
  • Parameters evaluated in multivariate analyses of these end points included primary site, T stage, primary tumor volume, N stage, histologic differentiation, fractionation schedule, adjuvant chemotherapy, and gender.
  • RESULTS: The rates of local control and local control without a severe late complication after RT were significantly influenced by primary tumor volume for patients with cancer of the supraglottic larynx and true vocal cord.
  • In contrast, the rates of local control and local control without severe complications for patients with tumors of the oropharynx and hypopharynx were less influenced by tumor volume.
  • Multivariate analyses stratified by primary site revealed that tumor volume significantly influenced local control for patients with cancers of the supraglottis (p =.0220) and glottis (p =.0042) but not for those with lesions of the tonsillar fossa/posterior tonsillar pillar (p =.0892), base of tongue (p =.9493), anterior tonsillar pillar/soft palate (p =.5909), and hypopharynx (p =.2282).
  • Primary tumor volume also significantly influences the probability of local control in cancers of the supraglottis and glottis.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Female. Fluorouracil / therapeutic use. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Predictive Value of Tests. Radiotherapy / adverse effects. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley Periodicals, Inc. Head Neck 25: 535-542, 2003
  • (PMID = 12808656.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Tucci R, Aburad De Carvalhosa A, Anunciação G, Daumas Nunes F, Dos Santos Pinto D Jr: Late diagnosis of a primary oral malignant melanoma: a case report. Minerva Stomatol; 2010 Jan-Feb;59(1-2):55-9
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late diagnosis of a primary oral malignant melanoma: a case report.
  • Eighty percent of the cases are located on the palate and maxillary gingiva, with the remainder found on the mandibular gingiva, buccal mucosa, tongue, and floor of the mouth.
  • OMM are highly aggressive with the tendency to metastasize and invade the surrounding tissues more readily than other oral malignancies.
  • The usual therapeutic approach for OMM is surgical excision of the primary tumor, supplemented by radiotherapy, with chemotherapy and immunotherapy serving as adjuvant.
  • Palpation revealed a painless soft tissue arising in maxillary gingiva, extending to the palate and vestibular mucosa.
  • The patient underestimated his symptoms and look for treatment after a substantial growth of the lesion.
  • This is an example of how a delayed detection affects the prognosis of OMM.
  • [MeSH-major] Gingival Neoplasms / diagnosis. Melanoma / diagnosis
  • [MeSH-minor] Adult. Delayed Diagnosis. Denial (Psychology). Fatal Outcome. Humans. Male. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20212410.001).
  • [ISSN] 0026-4970
  • [Journal-full-title] Minerva stomatologica
  • [ISO-abbreviation] Minerva Stomatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


11. Pogodzinski MS, Sabri AN, Lewis JE, Olsen KD: Retrospective study and review of polymorphous low-grade adenocarcinoma. Laryngoscope; 2006 Dec;116(12):2145-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most frequently affected sites were the hard palate (12 patients) and soft palate (9 patients).
  • Fifteen patients had their initial treatment at our institution, and four patients presented with a recurrent tumor.
  • One patient had regional nodal disease 20 years after the initial procedure, and another had lung metastasis.
  • No patients received chemotherapy.
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Retrospective Studies. Salivary Glands, Minor


12. Lengyel E, Baricza K, Somogyi A, Olajos J, Pápai Z, Godény M, Németh G, Esik O: Reirradiation of locally recurrent nasopharyngeal carcinoma. Strahlenther Onkol; 2003 May;179(5):298-305
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To study the efficacy of reirradiation as salvage treatment in patients with locally recurrent nasopharyngeal carcinoma.
  • PATIENTS AND METHODS: Between 1993 and 2000, 20 consecutive patients (twelve males and eight females) with nasopharyngeal cancer, previously irradiated in different Hungarian institutions, were reirradiated for biopsy-proven locally recurrent tumor.
  • Histologically, 85% of the patients had WHO type III, 5% type II, and 10% type I disease.
  • The median time period between termination of primary treatment and local recurrence was 30 (range, 10-204) months.
  • Brachytherapy was the method most frequently used: in ten cases alone (especially for rT1 tumors), and in eight cases in combination with external beam therapy.
  • Two patients with locally advanced disease underwent external beam therapy only.
  • The median dose in the event of brachytherapy alone was 20 Gy (4 x 5 Gy or 5 x 4 Gy, range, 16-36 Gy), and the dose range for exclusive external irradiation was 30-40 Gy.
  • In cases of combined irradiation, a median 20-Gy brachytherapy (range, 16-40 Gy) was associated with 30-40 Gy of external irradiation.
  • Radiotherapy was supplemented by neck dissection (six patients), nasopharyngectomy (one patient), or chemotherapy (eleven patients).
  • RESULTS: 16 patients were reirradiated once, three twice, and one patient three times, with a median equivalent dose for tumor effect of 36 Gy (mean, 44 Gy; range, 19-117 Gy; the estimated alpha/beta-ratio was 10 Gy).
  • The median equivalent dose of reirradiation for late effect on normal tissue (with an estimated 70% delivery of the tumor dose) amounted to 30 Gy (mean, 37 Gy; range, 13-101 Gy, estimated alpha/beta-ratio 3 Gy).
  • Seven of the twelve surviving patients are currently tumor-free.
  • After primary irradiation, xerostomy occurred in all patients as an unavoidable side effect of treatment.
  • Following reirradiation, a severe (grade 3 or higher) late toxicity (CTC criteria, version 2) has been observed in two tumor-free patients (10%) so far (necrosis of soft palate and paresis of glossopharyngeal nerve).
  • [MeSH-major] Nasopharyngeal Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Brachytherapy. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Radiotherapy / adverse effects. Radiotherapy Dosage. Survival Analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12740656.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


13. Rusthoven KE, Raben D, Schneider C, Witt R, Sammons S, Raben A: Freedom from local and regional failure of contralateral neck with ipsilateral neck radiotherapy for node-positive tonsil cancer: results of a prospective management approach. Int J Radiat Oncol Biol Phys; 2009 Aug 1;74(5):1365-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To review the outcomes of a prospective management approach using ipsilateral neck radiotherapy in the treatment of node-positive squamous cell carcinoma of the tonsil with a well-lateralized primary lesion.
  • METHODS AND MATERIALS: Between August 2003 and June 2007, 20 patients who presented with squamous cell carcinoma of the tonsil, without involvement of the base of the tongue or midline soft palate, and with Stage N1-N2b disease were prospectively treated with radiotherapy to the primary site and ipsilateral neck.
  • In addition, 18 patients received concurrent chemotherapy.
  • Acute and late toxicity were prospectively evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3, and Radiation Therapy Oncology Group criteria.
  • Late Radiation Therapy Oncology Group grade 2 xerostomia occurred in 1 patient (5%).
  • CONCLUSION: In carefully selected patients with node-positive, lateralized tonsillar cancer, treatment of the ipsilateral neck and primary site does not appear to increase the risk of contralateral nodal failure and reduces late morbidity compared with historical controls.
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / methods. Disease-Free Survival. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis / radiotherapy. Male. Middle Aged. Neck. Neoplasm Staging. Prospective Studies. Radiotherapy Dosage. Radiotherapy, Conformal / methods. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19168295.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Kulapaditharom B, Boonkitticharoen V: Photodynamic therapy in management of head and neck cancers and precancerous lesions. J Med Assoc Thai; 2000 Mar;83(3):249-58
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy in management of head and neck cancers and precancerous lesions.
  • Photodynamic therapy (PDT) is a new form of cancer treatment with low morbidity.
  • In this study, PDT was evaluated for its effectiveness in management of recurrent or widespread precancerous lesions, primary cancers in inoperable sites, recurrent or residual cancers which were refractory to radiotherapy and chemotherapy, and advanced tumors in the head and neck.
  • This was in contrast to cancers in the soft palate which failed in most cases possibly due to inadequate light dose distribution.
  • The mean follow-up time for this series was 28.3 months (range 3-66 months).
  • In conclusion, PDT is a useful modality for the treatment of head and neck tumors and precancerous lesions presenting in forms or under conditions that posed considerable difficulties in management by conventional approaches.
  • [MeSH-major] Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / pathology. Photochemotherapy / methods. Precancerous Conditions / drug therapy. Precancerous Conditions / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10808679.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] THAILAND
  •  go-up   go-down


15. Simon C, Goepfert H, Rosenthal DI, Roberts D, El-Naggar A, Old M, Diaz EM Jr, Myers JN: Presence of malignant tumor cells in persistent neck disease after radiotherapy for advanced squamous cell carcinoma of the oropharynx is associated with poor survival. Eur Arch Otorhinolaryngol; 2006 Apr;263(4):313-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presence of malignant tumor cells in persistent neck disease after radiotherapy for advanced squamous cell carcinoma of the oropharynx is associated with poor survival.
  • Non-surgical therapy consisting of external beam radiation with or without chemotherapy is an effective treatment for patients with squamous cell carcinoma (SCC) of the oropharynx with advanced neck disease (N2a or greater).
  • It is reported that nearly 50% of the neck dissection specimens contain residual viable tumor cells that may indicate partial radiation failure and as a consequence poor survival.
  • In order to address the significance of this finding, we conducted a nonrandomized retrospective study, including 35 patients who underwent definitive radiation therapy followed by either a radical or modified radical (RND/MRND) or a selective neck dissection (SND) for clinically persistent neck disease 6 weeks after completing therapy for stage III/IV SCC of the oropharynx (base of the tongue =15, tonsil =12, soft palate =7 and pharyngeal wall =1).
  • All neck dissection specimens were reviewed according to histological criteria indicating viable residual tumor.
  • The presence of malignant tumor cells in residual disease in the neck correlated with poor disease-specific and overall survival (P =0.03 and P =0.01, respectively).
  • In conclusion, the presence of viable cancer cells in radiated neck nodes is a novel prognostic marker for disease-specific survival in patients treated for SCCs of the oropharynx with advanced neck disease and may serve as an identifier for patients who will benefit from post-treatment chemoprevention.
  • [MeSH-minor] Adult. Aged. Cell Survival. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neck Dissection. Neoplasm, Residual. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(4):737-42 [1618666.001]
  • [Cites] Head Neck Surg. 1984 Jan-Feb;6(3):724-9 [6693288.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Mar;16(3):657-62 [2493434.001]
  • [Cites] Semin Radiat Oncol. 1992 Jul;2(3):163-170 [10717032.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jan 15;34(2):289-96 [8567328.001]
  • [Cites] Laryngoscope. 2000 Dec;110(12):2074-80 [11129024.001]
  • [Cites] Am J Surg. 1972 Oct;124(4):462-7 [5076159.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] Head Neck. 2002 May;24(5):474-81 [12001078.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):3964-71 [12351593.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 Apr;124(4):401-6 [9559686.001]
  • [Cites] Head Neck. 2003 Nov;25(11):960-7 [14603457.001]
  • [Cites] Cancer. 2002 Jun 1;94(11):2967-80 [12115386.001]
  • [Cites] Head Neck. 1998 Mar;20(2):132-7 [9484944.001]
  • [Cites] CA Cancer J Clin. 2004 May-Jun;54(3):150-80 [15195789.001]
  • [Cites] Head Neck. 1999 Oct;21(7):606-13 [10487947.001]
  • (PMID = 16328403.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Chao KS, Ozyigit G, Blanco AI, Thorstad WL, Deasy JO, Haughey BH, Spector GJ, Sessions DG: Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume. Int J Radiat Oncol Biol Phys; 2004 May 1;59(1):43-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume.
  • PURPOSE: To assess the therapeutic outcomes in oropharyngeal cancer patients treated with intensity-modulated radiotherapy (IMRT) and analyze the impact of primary gross tumor volume (GTV) and nodal GTV (nGTV) on survival and locoregional control rates.
  • Thirty-one patients received definitive IMRT; 17 also received platinum-based chemotherapy.
  • The mean prescription dose was 70 and 66 Gy, respectively, for the definitive and postoperative cohorts.
  • The daily fraction dose was either 1.9 or 2 Gy, five times weekly.
  • The GTV and/or nGTV were determined and derived using the Computational Environment for Radiotherapy Research, a free software package developed at Washington University.
  • Distant metastasis developed in 6 patients.
  • The 4-year estimate of overall survival was 87%, and the 4-year estimate of disease-free survival was 81% (66% in the definitive vs. 92% in the postoperative RT group).
  • The 4-year estimate of locoregional control was 87% (78% in the definitive vs. 95% in the postoperative RT group); the 4-year estimate of distant metastasis-free survival was 90% (84% in the definitive vs. 94% in the postoperative group).
  • Multivariate analysis showed that GTV and nGTV were independent risk factors determining locoregional control and disease-free survival for definitive oropharyngeal IMRT patients.
  • CONCLUSION: IMRT is an effective treatment modality for locally advanced oropharyngeal carcinoma.
  • The GTV and nGTV are the most important factors predictive of therapeutic outcome.
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Palate, Soft. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted. Statistics as Topic. Tongue Neoplasms / pathology. Tongue Neoplasms / radiotherapy. Tonsillar Neoplasms / pathology. Tonsillar Neoplasms / radiotherapy. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15093897.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. van Veen RL, Nyst H, Rai Indrasari S, Adham Yudharto M, Robinson DJ, Tan IB, Meewis C, Peters R, Spaniol S, Stewart FA, Levendag PC, Sterenborg HJ: In vivo fluence rate measurements during Foscan-mediated photodynamic therapy of persistent and recurrent nasopharyngeal carcinomas using a dedicated light applicator. J Biomed Opt; 2006 Jul-Aug;11(4):041107

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo fluence rate measurements during Foscan-mediated photodynamic therapy of persistent and recurrent nasopharyngeal carcinomas using a dedicated light applicator.
  • The objective of this study was to evaluate the performance of a dedicated light applicator for light delivery and fluence rate monitoring during Foscan-mediated photodynamic therapy of nasopharyngeal carcinoma in a clinical phase I/II study.
  • We have developed a flexible silicone applicator that can be inserted through the mouth and fixed in the nasopharyngeal cavity.
  • Three isotropic fibers, for measuring of the fluence (rate) during therapy, were located within the nasopharyngeal tumor target area and one was manually positioned to monitor structures at risk in the shielded area.
  • A flexible black silicon patch tailored to the patient's anatomy is attached to the applicator to shield the soft palate and oral cavity from the 652-nm laser light.
  • We observed a systematic reduction in fluence rate during therapy in 20 out of 26 illuminations, which may be related to photodynamic therapy-induced increased blood content, decreased oxygenation, or reduced scattering.
  • [MeSH-major] Lighting / instrumentation. Mesoporphyrins / therapeutic use. Nasopharyngeal Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Photochemotherapy / instrumentation
  • [MeSH-minor] Adolescent. Adult. Equipment Design. Equipment Failure Analysis. Female. Humans. Indonesia. Light. Male. Photosensitizing Agents / therapeutic use. Pilot Projects. Radiation Dosage. Radiometry. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965135.001).
  • [ISSN] 1083-3668
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mesoporphyrins; 0 / Photosensitizing Agents; FU21S769PF / temoporfin
  •  go-up   go-down






Advertisement